Atopic Dermatitis

The phase 1a study is a first in-human trial evaluating SYX-5219 for AD.

According to a survey, both patients and clinicians are unsatisfied with the current therapeutic landscape and are looking for options that better fulfill patient needs.

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis are particularly affected by social determinants of health, further impacting their outcomes.

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Panelists discuss the areas of research that need more attention in pediatric atopic dermatitis (AD) management, highlighting gaps in understanding the long-term effects of treatments, the genetic underpinnings of the disease, and strategies for improving early diagnosis and personalized care.

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.

Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.

Experts discussed personalized approaches to atopic dermatitis, from steroid-sparing topicals to biologics, highlighting rapid relief and long-term management strategies.

Research suggests that rebalancing the skin microbiome with pre-, post-, and probiotics may improve AD symptoms.

Experts discussed pediatric atopic dermatitis, treatment innovations, disease burden, and the latest topical and systemic therapies in a DermView video series.

When compared to corticosteroids alone, the combination therapy reduced disease severity and improved the skin barrier.

APG990 showed a 60-day half-life and favorable safety, supporting potential 3-6 month maintenance dosing for atopic dermatitis.

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

At a recent Dermatology Times Case-Based Roundtable event, James Q. Del Rosso, DO, discussed the limitations of topical corticosteroids and the benefits of nonsteroidals.

Objective tools like IGA and EASI provide structured severity assessment but often lack patient-reported insights such as itch severity.

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.

Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.

Professor Diamant Thaçi, MD, PhD, discusses findings from the ARCADIA and OLYMPIA clinical trial programs, highlighting nemolizumab’s rapid efficacy in treating atopic dermatitis and prurigo nodularis.

A PDUFA target action date has been set for October 13, 2025.